Christopher J. O’Callaghan

Queen's University — Canada

Medicine · Health Sciences

43h-index12.8kcitations189works11.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(60), Lung Cancer Treatments and Mutations(24), Gastric Cancer Management and Outcomes(24), Cancer Genomics and Diagnostics(18), Vector-borne infectious diseases(17)

Publications189 total

Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
Journal of Clinical Oncology·2026
The interplay of HLA diversity and copy loss, T-cell profiles, and immunotherapy efficacy in colorectal adenocarcinoma.
Journal of Clinical Oncology·2026
A randomized phase III trial of the impact of a structured exercise program on disease-free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE).
Journal of Clinical Oncology·2025· 6 cited
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
New England Journal of Medicine·2025· 137 cited
Concurrent mutations in DNA damage repair genes <i>BRCA1</i> , <i>POLE</i> , <i>ATM</i> and <i>FANCA</i> to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial.
Journal of Clinical Oncology·2025
Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours.
Journal of Clinical Oncology·2025
ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).
Journal of Clinical Oncology·2025· 14 cited
Cost-Utility Analysis of Durvalumab and Tremelimumab Versus Best Supportive Care in Refractory Metastatic Colorectal Cancer
Value in Health·2025
Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28).
Journal of Clinical Oncology·2025· 1 cited
Palliative radiotherapy for hepatic cancer pain – Authors' reply
The Lancet Oncology·2024
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study
The Lancet Oncology·2024· 23 cited
Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors.
Journal of Clinical Oncology·2024
Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer.
Journal of Clinical Oncology·2024· 1 cited
The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32.
Journal of Clinical Oncology·2024· 3 cited
Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial.
Journal of Clinical Oncology·2024
The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17
JNCI Journal of the National Cancer Institute·2024· 9 citedOpen Access
Clonal hematopoiesis of indeterminate potential (CHIP), treatment outcomes and adverse events in gastrointestinal cancers: A pooled analysis of clinical trial and real-world data.
Journal of Clinical Oncology·2024· 1 cited
P2.18-06 Co-designing an Experience of Care and Quality of Life Survey for an Australian Mesothelioma Clinical Outcomes Registry
Journal of Thoracic Oncology·2023Open Access
Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
Journal of Clinical Oncology·2023
Reversion of <i>RAS</i> mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial.
Journal of Clinical Oncology·2023· 1 cited
page 1 of 10Next →

Frequent Co-authors

Derek J. Jonker(9), Dongsheng Tu(8), Ian K. Barker(7), L. Robbin Lindsay(7), Dominique Charron(7), Niall C. Tebbutt(7), Keyue Ding(6), Daren K. Heyland(6), Abdel Maarouf(6), M. Bigras-Poulin(6), John Zalcberg(6), Graeme Rocker(5), Peter Dodek(5), N. H. Ogden(5), John Simes(5), Christos S. Karapetis(5), Demetrios J. Kutsogiannis(4), David Waltner‐Toews(4), Timothy Price(4), Jeremy Shapiro(4)